TARGET AUDIENCE

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer (OC).

OVERVIEW OF ACTIVITY
Gynecologic cancer comprises 5 primary types affecting the ovaries, uterine corpus (endometrial cancer), uterine cervix (cervical cancer), vulva and vagina. Of this group of diseases, OC has continually been the most lethal. The American Cancer Society estimates that 14,080 individuals will die of the disease in 2017, accounting for nearly 50% of the deaths attributable to all gynecologic cancers. Further, epithelial OC accounts for approximately 90% of malignant ovarian neoplasms and is thus the country’s fifth most common cause of cancer mortality in women. Primarily comprising the serous, endometrioid and mucinous cystadenocarcinoma histologies, epithelial OC is a challenging and often lethal medical condition. In fact, fewer than 40% of women with OC are ultimately cured and 70% present with advanced manifestations, at which point palliation and improvements in quality of life are the primary goals of therapy.

Although medical oncologists have been routinely responsible for counseling patients with regard to therapeutic decision-making, oncology nurses play an integral role in the successful delivery of systemic anticancer therapy and in preservation of patient physical and psychosocial well-being. These video proceedings from the sixth part of a 7-part integrated CNE curriculum originally held at the 2017 ONS Annual Congress feature discussions with leading OC investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

LEARNING OBJECTIVES

• Apply existing and emerging research data to the diagnostic, therapeutic and supportive care of patients with OC.
• Demonstrate knowledge of existing guidelines and consensus statements regarding the rationale for genetic counseling/testing for all patients with newly diagnosed OC, regardless of family history.
• Develop an understanding of the initial and long-term treatment of advanced OC considering the role of the anti-VEGF antibody bevacizumab.
• Implement an evidence-based approach to the prevention and amelioration of side effects associated with chemotherapeutic and biologic agents used in the management of OC.
• Appreciate the FDA approvals of olaparib, niraparib and rucaparib for patients with OC, and safely integrate these agents into the clinical care of appropriate individuals.
• Evaluate existing and emerging evidence supporting the use of PARP inhibitors as maintenance therapy for patients with recurrent, platinum-sensitive OC who are responding to platinum-based chemotherapy.
• Recall ongoing trials of other investigational approaches and agents in OC, and refer patients and obtain consent for study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
CNE credit is no longer available for this issue

ONCC/ILNA CERTIFICATION INFORMATION
CNE credit is no longer available for this issue

FOR SUCCESSFUL COMPLETION
This is a video CNE program.
CNE credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Kimberly Camp, RN, BSN, MSN, ANP-BC, ONC
Division of Gynecologic Oncology 
Duke Cancer Institute
Durham, North Carolina

Speakers Bureau: Depomed Inc.

Ursula A Matulonis, MD
Medical Director and Program Leader
Gynecologic Oncology Program
Associate Professor of Medicine
Harvard Medical School 
Dana-Farber Cancer Institute 
Boston, Massachusetts 

Advisory Committee: AstraZeneca Pharmaceuticals LP, Cerulean Pharma Inc, Clovis Oncology, Genentech BioOncology, ImmunoGen Inc, Lilly; Consulting Agreement: AstraZeneca Pharmaceuticals LP.

Michele Peetz, FNP-C
Gynecologic Oncology
Phoenix - Biltmore Cancer Center
Phoenix, Arizona

No relevant conflicts of interest to disclose.

Angeles Alvarez Secord, MD, MHSc
Professor 
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology 
Duke Cancer Institute
Durham, North Carolina 

Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Janssen Biotech Inc, Tesaro Inc; Contracted Research: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Eisai Inc, Endocyte Inc, Exelixis Inc, Genentech BioOncology, GlaxoSmithKline, Incyte Corporation, Merck, Morphotek Inc, Tesaro Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Tesaro Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: July 2017
Expiration date: July 2018

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.